Executive shake-up at Omnicom direct agency

Share this article:
Omnicom direct communications agency, LLKFB, has reported three upper-level management changes, including the promotion of one of the agency's co-founders to its top post and the departure of another.
LLKFB's president, Loreen Babcock, has taken on the title of chairman and chief executive of the agency.
Babcock co-founded LLKFB in 1996 along with Harry Koenig, who has left to be a consultnant for start-up companies. Another co-founder, Bob Lieber, left the LLKFB last year to start a consultancy called The Lieber Group.
Coming aboard in the newly created agency position of president and chief operating officer is David Finkel, who spent the past 14 years at the helm of EuroRSCG's Brann Worldwide.
The shakeup is the latest in a series of managerial changes at the agency following the November 2003 hiring of Joe Cupani as LLKFB's chief creative officer.
LLKFB clients include Abbott Laboratories, Bristol-Myers Squibb, Johnson & Johnson.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...